|
|
Post by mytakeonit on Apr 22, 2021 14:18:47 GMT -5
Same here peppy ... someone always posts these alerts anyway. Also, E*Trade will send me any important updates concerning MNKD.
But, that's mytakeonit
|
|
|
|
Post by Clement on Apr 23, 2021 8:41:50 GMT -5
I have a couple of friends my age (old guys) to whom I have mentioned MNKD. Each one was impressed with the company and its future, but commented, "I'm not gonna buy any stock under $5. When it goes above $5 I'll be a buyer."
|
|
|
|
Post by pat on Apr 23, 2021 8:43:45 GMT -5
Suspect that’s a common feeling among money managers as well. We could very well get some pretty good momentum as the year progresses.
|
|
|
|
Post by akemp3000 on Apr 23, 2021 9:41:19 GMT -5
Institutional investors are often prohibited from investing in stocks under $5. Conservative private investors also use that philosophy. It's all about risk versus reward. Conservative private investors should not be investing in biotechs anyway, especially small cap biotechs  |
|
|
|
Post by longliner on Apr 23, 2021 9:50:31 GMT -5
I am still wondering what the strategic plan is going forward for Afrezza?
We have watched the sales. Unless they have decided to start over AGAIN, something is in the works for Afrezza as little effort and energy seems to be going into sales, and this is reflected in the results.
I'm expecting a partnership with a BP for Afrezza. Pediatric trials for Afrezza was to be partnered as reported by MC last year. (I realize the dialogue has changed recently, maybe for negotiation reasons).
The company can then focus on existing and new Technosphere applications. Afrezza would remain a revenue stream that fits nicely with the technosphere licensing model.
When Mannkind can articulate and execute on a clear functional business plan and vision, one that encompasses all of their products, and is exciting to future partners, then I believe Wall Street will get onboard.
|
|
|
|
Post by mytakeonit on Apr 23, 2021 13:25:02 GMT -5
May 20th isn't that far away. And remember that it isn't all about Afrezza. And lastly, if I waited for $5 to buy into MNKD ... I would have only 1/6 the number of shares now.  But, that's mytakeonit (The REALLY OLD GUY) |
|
|
|
Post by longliner on Apr 23, 2021 17:27:35 GMT -5
|
|
|
|
Post by MnkdWASmyRtrmntPlan on Apr 24, 2021 5:01:44 GMT -5
A good little article, longliner. More wisdom from Mark Hulbert (the author of that article). Mark's "Hulbert Ratings" are what introduced me to Nate Pile, who introduced me to Al Mann and Mannkind (so many years ago). I like to think of it all as sound financial advice. |
|
|
|
Post by BD on Apr 24, 2021 9:50:30 GMT -5
I don't think the article said anything about Renaissance being "ethical", just that it wasn't/isn't a scam. |
|
|
|
Post by longliner on Apr 24, 2021 10:01:19 GMT -5
I don't think the article said anything about Renaissance being "ethical", just that it wasn't/isn't a scam. I stand corrected, it's not a scam if you know how the FDA will rule ahead of time. But it sure does boost your returns. |
|
|
|
Post by prcgorman2 on Apr 24, 2021 11:54:12 GMT -5
I am still wondering what the strategic plan is going forward for Afrezza? We have watched the sales. Unless they have decided to start over AGAIN, something is in the works for Afrezza as little effort and energy seems to be going into sales, and this is reflected in the results. I'm expecting a partnership with a BP for Afrezza. Pediatric trials for Afrezza was to be partnered as reported by MC last year. (I realize the dialogue has changed recently, maybe for negotiation reasons). The company can then focus on existing and new Technosphere applications. Afrezza would remain a revenue stream that fits nicely with the technosphere licensing model. When Mannkind can articulate and execute on a clear functional business plan and vision, one that encompasses all of their products, and is exciting to future partners, then I believe Wall Street will get onboard. Afrezza is the reason MC gave for approaching Mannkind management about coming to work for them. He’s said more than once he thinks the long-term prospects for Afrezza are extremely good especially for pediatric T1s who he has said he believes will be adult customers. Sales have lagged, but that was an expected outcome of the COVID lockdowns, most of which are still in place to one degree or another. So, I can’t say what the strategy with regard to Afrezza is, but I doubt (and hope it is not) another attempt to find a marketing partner except perhaps outside the US similar to what they’ve done in Brazil, India, and Australia. I also hope they do not spend significant money on marketing Afrezza until TreT revenues are on-line. I think it would be good to re-build the sale/marketing they had in place pre-COVID, but I’ve been convinced by doctors and other who’ve posted on Proaboards that the real roadblocks to effective sales of Afrezza are the lack of insurance coverage on par with Humlog and Novolog, and lack of prescriber confidence. Take care of those 2 main challenges, and then open the pocketbook for scaling up the salesforce and DTC advertising. All of that will take years. |
|
|
|
Post by buyitonsale on Apr 24, 2021 13:53:02 GMT -5
I think that "lack of prescriber confidence" in reality is just a "lack of prescriber interest" to improve patient's outcomes. Insurance coverage is not a major barrier once the paperwork is started and 8 out of 10 are approved, per information from MNKD. Most people are not at A1C goal and time in range is not where it should be either. Patients need to wake up and not trust their providers that much, when results are not there... On top of that ADA has people believing that eating high carb diet is fine as long as you choose "healthy" options, and most providers concur. That is a separate topic but an obvious pitfall when trying to manage diabetes. My point is that providers are not trying hard enough and diabetes statistics prove it. Pancakes, muffins and fruit smoothies anyone ? www.diabetes.org/healthy-living/recipes-nutrition/meal-planningwww.diabetesfoodhub.org/diabetes-diabetic-breakfast-recipes.html |
|
|
|
Post by mymann on Apr 24, 2021 14:47:02 GMT -5
It takes time to personalize insulin therapy. Sliding scale is used by uninformed primary care physicians as their go to institutions for starting and maintaining glucose control. Giving pills is simple and saves time for physicians. Physicians are more afraid of hypoglycemia law suits and not willing to change the prescribing habits even if there's better options. We are bunch of lazy professionals. I have been in emergency room in a busy high volume hospital and never came across a patient that is on Afrezza.
|
|
|
|
Post by cretin11 on Apr 24, 2021 15:29:23 GMT -5
If only there were a company that was established to treat PWDs and that understood Afrezza should be the go-to treatment option...
|
|
|
|
Post by sportsrancho on Apr 24, 2021 17:10:44 GMT -5
Yes yes and yes!!! To the last three posts! Exactly
|
|
